WO2001070772A3 - Molecule d'interet pharmaceutique comportant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide - Google Patents

Molecule d'interet pharmaceutique comportant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide Download PDF

Info

Publication number
WO2001070772A3
WO2001070772A3 PCT/FR2001/000872 FR0100872W WO0170772A3 WO 2001070772 A3 WO2001070772 A3 WO 2001070772A3 FR 0100872 W FR0100872 W FR 0100872W WO 0170772 A3 WO0170772 A3 WO 0170772A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
glutamine
molecule
terminal
addition salt
Prior art date
Application number
PCT/FR2001/000872
Other languages
English (en)
Other versions
WO2001070772A2 (fr
Inventor
Christine Klinguer-Hamour
Nathalie Corvaia
Alain Beck
Liliane Goetsch
Original Assignee
Pf Medicament
Christine Klinguer-Hamour
Nathalie Corvaia
Alain Beck
Liliane Goetsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament, Christine Klinguer-Hamour, Nathalie Corvaia, Alain Beck, Liliane Goetsch filed Critical Pf Medicament
Priority to CA002403803A priority Critical patent/CA2403803A1/fr
Priority to BR0109502-1A priority patent/BR0109502A/pt
Priority to MXPA02009359A priority patent/MXPA02009359A/es
Priority to JP2001568973A priority patent/JP2003528112A/ja
Priority to EP01919544A priority patent/EP1305332A2/fr
Priority to AU2001246623A priority patent/AU2001246623A1/en
Publication of WO2001070772A2 publication Critical patent/WO2001070772A2/fr
Publication of WO2001070772A3 publication Critical patent/WO2001070772A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

La présente invention a pour objet une molécule d'intérêt pharmaceutique, de préférence un ligand du Complexe Majeur d'Histocompatibilité (CMH), comportant un acide glutamique ou une glutamine à son extrémité N-terminale, qui se présente sous forme de sel d'addition d'acide fort physiologiquement acceptable, ainsi qu'un vaccin comprenant un tel ligand.
PCT/FR2001/000872 2000-03-23 2001-03-22 Molecule d'interet pharmaceutique comportant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide WO2001070772A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002403803A CA2403803A1 (fr) 2000-03-23 2001-03-22 Molecule d'interet pharmaceutique comportant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
BR0109502-1A BR0109502A (pt) 2000-03-23 2001-03-22 Molécula de interesse farmacêutico, composição farmacêutica, vacina, método de diagnóstico in vitro de patologias associadas com a presença em um corpo de paciente de ligandos do mhc, pacote ou kit para execução de métodos de diagnóstico in vitro, utilizações de um ligando e de um ácido forte, e, processo de preparação e de estabilização de uma molécula de interesse farmacêutico
MXPA02009359A MXPA02009359A (es) 2000-03-23 2001-03-22 Molecula de interes farmaceutico que contiene en su extremo n-terminal, un acido glutamico o una glutamina en la forma de una sal de adicion fisiologicamente aceptable acido fuerte.
JP2001568973A JP2003528112A (ja) 2000-03-23 2001-03-22 強酸との生理学的に許容しうる付加塩の形態の、ｎ末端にグルタミン酸またはグルタミンを含む薬剤として有用な分子
EP01919544A EP1305332A2 (fr) 2000-03-23 2001-03-22 Molecule d'internet pharmaceutique comportant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide
AU2001246623A AU2001246623A1 (en) 2000-03-23 2001-03-22 Molecule of pharmaceutical interest comprising at its N-terminal a glutamic acid or a glutamine in the form of an addition salt to an acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0003711A FR2806727A1 (fr) 2000-03-23 2000-03-23 Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
FR00/03711 2000-03-23

Publications (2)

Publication Number Publication Date
WO2001070772A2 WO2001070772A2 (fr) 2001-09-27
WO2001070772A3 true WO2001070772A3 (fr) 2003-02-13

Family

ID=8848421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/000872 WO2001070772A2 (fr) 2000-03-23 2001-03-22 Molecule d'interet pharmaceutique comportant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide

Country Status (11)

Country Link
US (1) US20030175285A1 (fr)
EP (1) EP1305332A2 (fr)
JP (1) JP2003528112A (fr)
CN (1) CN1449407A (fr)
AU (1) AU2001246623A1 (fr)
BR (1) BR0109502A (fr)
CA (1) CA2403803A1 (fr)
FR (1) FR2806727A1 (fr)
MX (1) MXPA02009359A (fr)
WO (1) WO2001070772A2 (fr)
ZA (1) ZA200207632B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
EP1395276A4 (fr) * 2001-05-15 2004-12-29 Ludwig Inst Cancer Res Peptides structurellement modifies et leurs utilisations
JP2008500006A (ja) * 2003-05-21 2008-01-10 バイオテック トゥールス ソシエテ アノニム ペプチド複合体
ES2396231T3 (es) 2003-05-21 2013-02-20 Biotech Tools S.A. Complejo peptídico
CN102659922B (zh) * 2003-09-22 2013-11-06 株式会社绿多肽 来源于c型肝炎病毒的肽
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
BRPI0504117A (pt) 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
GB0522748D0 (en) * 2005-11-07 2005-12-14 Univ Cambridge Tech Collagen peptides, methods and uses
AU2007207618B2 (en) * 2006-01-18 2011-03-24 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions with enhanced stability
SI2083856T1 (sl) 2007-08-15 2011-02-28 Circassia Ltd Peptidi za desenzibilizacijo proti alergijam
WO2010022740A2 (fr) * 2008-08-28 2010-03-04 Aarhus Universitet Polypeptides d’enveloppe du vih-1 pour un vaccin contre le vih
WO2011034207A1 (fr) 2009-09-16 2011-03-24 Senju Pharmaceutical Co., Ltd. Peptide partiel de lacritine
LT2547364T (lt) * 2010-03-15 2017-03-27 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Peptidai, konjugatai ir vakcinos imunogeniškumo padidinimo būdas
EP2748186A1 (fr) * 2011-08-23 2014-07-02 Skau Aps Procédé d'élimination des propriétés immunosuppressives des glycoprotéines d'enveloppe du vih
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
KR20170126001A (ko) * 2015-03-30 2017-11-15 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 면역용 펩티드, 면역용 펩티드의 제조 방법, 그것을 포함하는 면역 질환용 의약 조성물, 및 면역 질환의 치료 방법
CN113227124A (zh) * 2018-10-31 2021-08-06 味之素株式会社 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079231A (en) * 1988-07-29 1992-01-07 Ellem Industria Farmaceutica S.P.A. Immunostimulating peptides, a process for their preparation and pharmaceutical compositions containing them
WO1994004171A1 (fr) * 1992-08-11 1994-03-03 President And Fellows Of Harvard College Peptides immunomodulateurs
US5844075A (en) * 1994-04-22 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
WO1998058951A1 (fr) * 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Nonapeptides et decapeptides isoles se fixant a des molecules hla, et leur utilisation
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications
WO1999050637A2 (fr) * 1998-03-27 1999-10-07 Ludwig Institute For Cancer Research Complexes multicomposants isoles servant a l'analyse des lymphocytes t, peptides utiles a la fabrication de ces complexes et utilisations de ces complexes
WO1999055730A2 (fr) * 1998-04-27 1999-11-04 Chiron S.P.A. Proteine porteuse de polyepitopes

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079231A (en) * 1988-07-29 1992-01-07 Ellem Industria Farmaceutica S.P.A. Immunostimulating peptides, a process for their preparation and pharmaceutical compositions containing them
WO1994004171A1 (fr) * 1992-08-11 1994-03-03 President And Fellows Of Harvard College Peptides immunomodulateurs
US5844075A (en) * 1994-04-22 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
WO1998058951A1 (fr) * 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Nonapeptides et decapeptides isoles se fixant a des molecules hla, et leur utilisation
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications
WO1999050637A2 (fr) * 1998-03-27 1999-10-07 Ludwig Institute For Cancer Research Complexes multicomposants isoles servant a l'analyse des lymphocytes t, peptides utiles a la fabrication de ces complexes et utilisations de ces complexes
WO1999055730A2 (fr) * 1998-04-27 1999-11-04 Chiron S.P.A. Proteine porteuse de polyepitopes

Also Published As

Publication number Publication date
WO2001070772A2 (fr) 2001-09-27
ZA200207632B (en) 2003-10-27
CN1449407A (zh) 2003-10-15
AU2001246623A1 (en) 2001-10-03
MXPA02009359A (es) 2003-02-12
FR2806727A1 (fr) 2001-09-28
EP1305332A2 (fr) 2003-05-02
US20030175285A1 (en) 2003-09-18
JP2003528112A (ja) 2003-09-24
BR0109502A (pt) 2004-01-13
CA2403803A1 (fr) 2001-09-27

Similar Documents

Publication Publication Date Title
WO2001070772A3 (fr) Molecule d'interet pharmaceutique comportant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide
CY2016024I2 (el) ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ
MXPA05002814A (es) Formulacion para agentes lipofilicos.
HK1067544A1 (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
ZA200206905B (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same.
NO331093B1 (no) Somatostatinanaloger, fremgangsmåte for fremstilling, farmasøytisk sammensetning og anvendelse derav.
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
AP2004003055A0 (en) Platinum derivative pharmaceutical formulations.
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
IL162185A0 (en) Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
MXPA03006538A (es) Nuevos derivados de urea, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.
NO20034863D0 (no) Deuterert 3-piperidinopropiofenon og medikamenter inneholdende disse
WO2002056708A3 (fr) Preparation destinee a ameliorer l'assimilation des aliments
WO1998019697A3 (fr) Compositions pharmaceutiques nouvelles
HUP0302193A3 (en) 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation thereof and pharmaceutical compositions containing them
WO2002062304A3 (fr) Agents cosmetiques et/ou pharmaceutiques
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
WO2002102345A3 (fr) Deferoxamine comme inhibiteur de no-synthase et utilisations
HK1060129A1 (en) Novel piperidinecarboxamide derivatives, method f or preparing same and pharmaceutical compositions containing same.
HUP0500958A2 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them
WO2007044574A3 (fr) Compositions pharmaceutiques, leurs procedes de preparation, et procedes de traitement
IL154986A0 (en) Triazolo-epothilone derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10239313

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 568973

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001919544

Country of ref document: EP

Ref document number: 2002/07632

Country of ref document: ZA

Ref document number: PA/a/2002/009359

Country of ref document: MX

Ref document number: 200207632

Country of ref document: ZA

Ref document number: 2403803

Country of ref document: CA

Ref document number: 2001246623

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 018088333

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001919544

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001919544

Country of ref document: EP